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Abstract: Mixed dyslipidemia is a common lipid disorder characterized by the presence of 
an atherogenic lipoprotein phenotype due to abnormalities in various atherogenic and anti-
atherogenic lipoproteins. Despite the link between the decrease of LDL-cholesterol by statin 
treatment and the prevention of cardiovascular disease, a high residual risk is observed in 
statin trials. This residual risk is partly explained by lipoprotein abnormalities other than LDL. 
Fenoﬁ  brate exerts a favorable effect on the atherogenic lipid proﬁ  le of mixed dyslipidemia and 
can effectively reduce cardiovascular disease in patients with mixed dyslipidemia. Fenoﬁ  brate 
may offer important treatment alternatives as a second-line therapy in several circumstances: 
in combination with a statin for patients with mixed dyslipidemias not at goals on statin mono-
therapy; in monotherapy for patients intolerant or with contraindication to statin therapy; and in 
combination with other drugs (ezetimibe, colesevelam) for patients with mixed dyslipidemias, 
known intolerance, or contraindication to statin and not at goals on fenoﬁ  brate monotherapy. 
However, the role of fenoﬁ  brate-statin therapy and of other therapies involving fenoﬁ  brate in 
cardiovascular risk reduction strategies remains to be established.
Keywords: fenofibrate, mixed dyslipidemia, triglycerides, LDL-cholesterol, HDL-
cholesterol
Around the world, cardiovascular disease (CVD) is the leading cause of deaths for adults 
(World Health Statistics 2008). The most important modiﬁ  able cardiovascular risk factors 
are smoking, hypertension, dyslipidemia, obesity (mainly central) and hyperglycemia. 
These risk factors are often clustered, particularly for patients with type 2 diabetes and/or 
metabolic syndrome. Among dyslipoproteinemia, mixed or combined hyperlipidemia 
is a common disorder, occurring in about 30% of myocardial infarction (MI) survivors 
(Durrington 2003). Mixed dyslipidemia is characterized by elevated levels of triglycerides 
(TG) and reduced high-density lipoprotein cholesterol (HDL-C), with or without elevated 
levels of low-density lipoprotein cholesterol (LDL-C). This atherogenic lipoprotein phe-
notype is usually associated with a preponderance of small, dense LDL particles and an 
elevated apolipoprotein B (ApoB) concentration. All the metabolic abnormalities of mixed 
dyslipidemia contribute to increase risk for CVD. Mixed dyslipidemia can be genetically 
determined such as in familial combined hyperlipidemia and is also the must frequent 
lipid disorder found in patients with type 2 diabetes and metabolic syndrome (Best and 
O’Neal 2000; Szapary and Rader 2004). This review updates the management of mixed 
dyslipidemia and particularly on the clinical utility of fenoﬁ  brate in mixed dyslipidemia.
Management of mixed dyslipidemia
Mixed dyslipidemia is usually characterized by elevated LDL-C and TG and decreased 
HDL-C levels. Although plasma levels of LDL-C may be normal or only slightly Vascular Health and Risk Management 2008:4(5) 992
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above target levels, an increase in atherogenic small, dense 
LDL is a common feature, as well as elevated non-HDL-C 
and ApoB levels. Numerous landmark trials involving HMG-
CoA reductase inhibitors (statins) have ﬁ  rmly demonstrated 
that LDL-C lowering signiﬁ  cantly reduces total mortality and 
CVD morbidity and mortality (CTT Collaborators 2005). 
Therefore, the use of statins has become the cornerstone of 
lipid lowering therapy in reducing the risk of CVD. Statins 
are indicated as ﬁ  rst-line therapy for patients for primary 
hypercholesterolemia and mixed dyslipidemia. Moreover 
recent trials comparing different statin treatments have shown 
that intensive LDL-C lowering regimens are signiﬁ  cantly 
more effective than moderate treatments in reducing coronary 
events and atherosclerotic progression (Nissen et al 2004; 
Cannon et al 2006).
Elevated LDL-C is identiﬁ  ed as the primary target of 
lipid-lowering therapy by both US (NCEP ATP III 2001; 
Grundy et al 2004a) and European (European guidelines 
2007; The Task Force on Diabetes 2007) guidelines. These 
guidelines speciﬁ  ed LDL-C of 100 mg/dL (2.6 mmol/L) as a 
minimal goal of treatment in high risk patients. For patients at 
very high risk, a new therapeutic option for LDL-C is below 
70 to 80 mg/dL (2 mmol/L). The National Cholesterol 
Education Program Adult Treatment Panel III (NCEP ATP 
III) recognized both low HDL-C (40 mg/dL) and elevated 
TG (150 mg/dL) as markers of increased CVD risk. Beyond 
lowering LDL-C, the NCEP ATP III introduced a second-
ary target of therapy, non-HDL-C, in patients with elevated 
TG. In some studies, non-HDL-C has been reported to be a 
stronger predictor of CVD risk than LDL-C (Cui et al 2001; 
Ridker et al 2005). More recently, in a post hoc analysis 
of TNT and IDEAL trials (Kastelein et al 2008), on-statin 
treatment levels of non-HDL-C and apolipoprotein B were 
more closely associated with cardiovascular outcome than 
LDL-C levels, supporting the use of non-HDL-C as a novel 
treatment target. The goal for non-HDL-C at any level of risk 
is 30 mg/dL higher than the LDL-C treatment goal. Thus, 
in patients with mixed dyslipidemia and very high risk (ie, 
with CVD and diabetes or the metabolic syndrome (Grundy 
et al 2004a) who have an LDL-C goal of 70 mg/dL, the 
non-HDL-C goal is 100 mg/dL. The coronary risk is also 
associated with mildly elevated (150–500 mg/dL) plasma 
TG level. Very high levels of TG (500 mg/dL) are a risk 
for acute pancreatitis.
In high risk patients with mixed dyslipidemia, an ideal 
treatment should deal with the global spectrum of the ath-
erogenic lipid triad (high LDL-C, low HDL-C and high TG). 
High levels of LDL-C could be effectively controlled with a 
statin. However statin therapy may be limited by the failure 
to reach non-HDL-C goals and sometimes by intolerance or 
poor response in monotherapy. Several considerations have 
led to increased interest in non-statin options for correction 
of mixed dyslipidemia:
–  Low HDL-C is associated with increased CVD risk 
(Gordon et al 1977, 1989). The Framingham study indi-
cated a clear relationship between low HDL-C levels 
and increased risk of coronary disease, irrespective of 
LDL-C levels (Gordon et al 1977). In a meta-analysis of 
four large prospective studies (Gordon et al 1989), every 
1 mg/dL decrease in HDL-C is associated with increased 
risk of coronary heart disease (CHD), differently in males 
and females (2% males and 3% females), independent of 
other risk factors, including LDL-C levels.
–  Even if TG have been a controversial risk factor, recent 
epidemiologic evidences have demonstrated that elevated 
TG independently predicts CVD. A recent meta-analysis 
of 29 prospective studies enrolling 262,525 subjects 
indicated a strong and highly signiﬁ  cant association 
between TG values and CHD risk (Sarwar et al 2007). 
Two additional studies have corroborated these ﬁ  ndings 
(Bansal et al 2007; Nordestgaard et al 2007), both studies 
supporting the concept that non-fasting TG levels may 
strongly predicts the CVD risk (McBride 2007). In mixed 
dyslipidemia, post-prandial triglyceride-rich lipoproteins 
are typically increased with a delay in the clearance of 
these lipoprotein particles and a prolonged exposure.
–  Although statins are clearly effective in lowering LDL-C 
levels, this class of drugs appear to have more modest 
effects in terms of raising HDL-C and lowering TG. 
Statins have been reported to raise HDL-C levels by 
5% to 15% and to lower TG by 7% to 30% (NCEP ATP 
III 2001).
–  Finally in landmark statin clinical trials, high “residual” 
CVD risk can be partly explained by the presence of 
lipoprotein abnormalities other than LDL. Indeed, sub-
jects treated with a statin but who had low HDL-C levels 
remained at a greater CVD risk than those with normal 
or high HDL-C levels. In a recent post-hoc analysis 
of the Treating to New Targets (TNT) trial, levels of 
HDL-C were inversely related to the risk of major CVD 
events among CHD patients receiving statin treatment 
(Barter et al 2007). Even in patients with LDL-C at or 
below the optional treatment target of 70 mg/dL, those 
who were in the lowest HDL-C quintile had a signiﬁ  -
cantly increased CVD risk compared with those in the 
highest HDL-C quintile (Barter et al 2007). Interestingly Vascular Health and Risk Management 2008:4(5) 993
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a similar ﬁ  nding has been found for TG levels in a 
complementary analysis of PROVE-IT TIMI-22 trial 
(Miller et al 2008): compared with individuals who 
achieved low levels of both LDL-C (70 mg/dL) and 
TG (150 mg/dL), patients with higher levels of on-
treatment LDL-C and/or TG had signiﬁ  cantly elevated 
risk of CHD events. On-treatment TG 150 mg/dL was 
independently associated with a lower risk of recurrent 
CHD effects.
Conversely, a number of studies have demonstrated that treat-
ment with ﬁ  brates or niacin (with or without a statin) improves 
the atherogenic lipoprotein proﬁ  le and/or reduces cardiovascular 
morbidity and mortality. Among these drugs, this review only 
reports arguments for a clinical utility of fenoﬁ  brate.
Mechanism of action of fenoﬁ  brate
Fenoﬁ  brate belongs to a class of drugs that exert their effects 
by activating the peroxisome proliferator-activated receptor α 
(PPARα), a transcription factor that regulates lipid metabo-
lism via a number of routes. Activated PPARα stimulates the 
expression of genes encoding various enzymes that regulate 
fatty acid and lipoprotein metabolism (Fruchart et al 2001; 
Fazio and Linton 2004; Keating and Croom 2007). Fenoﬁ  brate 
stimulated the oxidation of free fatty acids in the liver. This 
promotion of the β-oxidation of fatty acids reduced the 
availability of fatty acids for very-low density lipoprotein 
(VLDL) synthesis and secretion. Fenoﬁ  brate also increased 
the expression of the gene for lipoprotein lipase and decreases 
ApoC-III expression in the liver. Thus, fenoﬁ  brate lowered the 
concentration of TG both by reducing the rate of synthesis and 
increasing the rate of hydrolysis of triglyceride-rich lipopro-
teins (Staels et al 1998; Keating and Croom 2007). Moreover, 
fenoﬁ  brate treatment reduced the proportion of small, dense 
LDL, with the formation of larger, less dense LDL particles 
with a higher afﬁ  nity for the LDL receptor and thus catabo-
lized more rapidly (Chapman 2006). PPARα activation with 
fenoﬁ  brate also increased expression of the genes for both 
ApoA-I and ApoA-II, decreased the cholesteryl ester transfer 
protein-mediated transfer of cholesterol from HDL to VLDL, 
enhanced cell cholesterol efﬂ  ux by induction of cell ABCA1 
expression and decreased SR-B1 in the liver. All these effects 
contribute to the increase of plasma HDL-C concentrations 
(Guerin et al 1996; Chinetti et al 2001; Mardones et al 2003; 
Fruchart and Duriez 2006).
In addition to the lipid-modifying activity, fenoﬁ  brate also 
had numerous pleiotropic effects mediated by PPARα activa-
tion (Staels et al 1998; Paumelle and Staels 2008): fenoﬁ  brate 
improved endothelial function (Playford et al 2002; Capell 
et al 2003; Koh et al 2005) and exerted anti-inﬂ  ammatory 
activities (Zambon et al 2006; Rosenson et al 2008) as 
evidenced by a reduction in CRP as well as a number of 
cytokines (eg, IL-6, TNF-alpha) In patients with metabolic 
syndrome and elevated TG, fenofibrate reduced whole 
blood production of inﬂ  ammatory cytokines and hepatic-
synthesized inﬂ  ammatory proteins, and the anti-inﬂ  ammatory 
effects of fenoﬁ  brate involve VLDL- and LDL-mediated 
pathways (Rosenson et al 2008). Fenoﬁ  brate also decreased 
procoagulant factors such as ﬁ  brinogen and plasminogen acti-
vator inhibitor-1 (Kaneko et al 2002; Maison et al 2002) and 
reduced monocyte chemoattractant protein-1 (Keating and 
Ormrod 2002; Paumelle and Staels 2008). Among ﬁ  brates, 
only fenoﬁ  brate signiﬁ  cantly reduced uric acid levels (Liamis 
et al 1999; Keating and Ormrod 2002).
In contrast, fenoﬁ  brate therapy induced two potential 
deleterious effects: an increase in creatinine (Keating and 
Ormrod 2002; Tsimichodimos et al 2002) and homocysteine 
levels (Keating and Ormrod 2002; Dierkes et al 2003). 
Whether these effects on creatinine and homocysteine are 
of clinical importance remains to be determined. Creatinine 
rises was not associated with an alteration in renal function, 
as measured by glomerular ﬁ  ltration rate (Hottelart et al 
2002). The creatinine elevation associated with fenoﬁ  brate 
treatment is fully reversible within a few weeks of ceasing 
therapy (The FIELD study investigators 2005), also suggest-
ing an absence of permanent renal damage.
The potential of monotherapy with fenoﬁ  brate in the 
treatment of patients with primary dyslipidemia has been well 
established in numerous, placebo-controlled and comparative 
trials (Adkins and Faulds 1997; Keating and Ormrod 2002). 
The effect of fenoﬁ  brate on the concentration of plasma lipids 
is largely inﬂ  uenced by the baseline lipid levels. Fenoﬁ  brate 
therapy was consistently associated with a substantial decreases 
of serum TG by 20% to 50%, usually directly proportional to 
the baseline TG levels. Fenoﬁ  brate increased HDL-C levels 
by 10% to 25%, to a degree directly dependent of baseline TG 
and HDL-C levels. Fenoﬁ  brate had widely variable effects on 
LDL-C levels mainly dependent of the type of dylipidemia. For 
example, fenoﬁ  brate may decrease LDL-C by 20% in patients 
with normal TG levels, but generally produces less reduction 
in LDL-C in patients with mixed dyslipidemia. Patients with 
severe hypertriglyceridemia and low levels of LDL-C may 
raise their LDL-C levels during fenoﬁ  brate treatment, possibly 
as a result of an accelerated catabolism of triglyceride-rich 
lipoproteins, leading to an increased LDL conversion and an 
increased LDL particle size. This increase in LDL size may 
constitute an antiatherogenic mechanism.Vascular Health and Risk Management 2008:4(5) 994
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Clinical utility of fenoﬁ  brate
in mixed dyslipidemia
Clinical efﬁ  cacy in monotherapy
A meta-analysis of randomized ﬁ  brate trials (1,457 patients 
receiving fenoﬁ  brate) realized across a range of popula-
tions, found that fenofibrate decreased LDL-C and TG 
respectively by 11% and 40% and increased HDL-C by 10% 
(Birjmohun et al 2005).
Although the effect of fenoﬁ  brate on LDL-C in these stud-
ies was variable, it was generally smaller than that achieved 
with statins. Two recent trials (Farnier et al 2005; Farnier et al 
2007) provided data on the efﬁ  cacy of fenoﬁ  brate monotherapy 
in large populations of patients with mixed dyslipidemia: 
in these trials, TG decreased by 43.2% and 41.3%, HDL-C 
increased by 18.8% and 18.2%, LDL-C decreased by 5.5% 
and 15.7%, and non-HDL-C decreased by 16.2% and 21.0% 
(Farnier et al 2005; Farnier et al 2007). The effects on ApoB 
were in agreement with the evolution of non-HDL-C levels: 
ApoB levels decreased by 15.2% and 20.1%. ApoA-I levels 
were increased by 8.4% and 10.8% (Farnier et al 2005; Farnier 
et al 2007). Finally these trials have conﬁ  rmed a large and 
signiﬁ  cant shift in LDL size with a decrease in the proportion 
of small, dense LDL during fenoﬁ  brate treatment. In summary, 
fenofibrate has a favorable action on all the lipoprotein 
abnormalities present in patients with mixed dyslipidemia.
This pattern of mixed dyslipidemia with high TG, low 
HDL-C and preponderance of small dense LDL is usually 
observed in type 2 diabetes and metabolic syndrome. 
Presumably to follow-up on the favorable effects of gemﬁ  -
brozil treated diabetic patients in Helsinki Heart Study (HHS) 
and Veterans Affairs High-Density Lipoprotein Cholesterol 
Intervention Trial (VA-HIT) study, the potential role of 
fenoﬁ  brate for CVD risk reduction has only been evaluated 
in type 2 diabetes, but not speciﬁ  cally type 2 diabetic patients 
with mixed dyslipidemia.
In the Diabetes Atherosclerosis Intervention Study   
(DAIS 2001), 418 diabetic men and women were random-
ized to fenoﬁ  brate or placebo for 3 years. Baseline lipids 
were LDL-C of 132 mg/dL, TG of 221 mg/dL, and HDL-C 
of 40 mg/dL. Fenoﬁ  brate lowered LDL-C by 6% and TG 
by 28%, and raised HDL-C by 7%. Fenoﬁ  brate slowed the 
angiographic progression of coronary atherosclerosis: the 
progression of focal coronary atheroma was 40% less in the 
fenoﬁ  brate group compared with placebo, without signiﬁ  cant 
effect on diffuse atheroma. Interestingly, although the study 
was not powered to look at clinical events, there was a non 
signiﬁ  cant 23% reduction in CVD events. These effects 
seemed to be explained not only by the changes in HDL-C, 
LDL-C and TG levels, but also by a signiﬁ  cant increase in 
LDL particle size (Vakkilainen et al 2003). Additionally, 
fenoﬁ  brate reduced the incidence of microalbuminuria by 
54% (Ansquer et al 2005). In DAIS, the increase of homo-
cysteine did not alter the beneﬁ  cial effect of fenoﬁ  brate 
(Genest et al 2004).
The Fenoﬁ  brate Intervention and Event Lowering in 
Diabetes (FIELD) was the ﬁ  rst large landmark cardiovascular 
event-based trial with fenoﬁ  brate (The FIELD study inves-
tigators 2005). FIELD was a 5-year, randomized, placebo-
controlled, double-blind study of the efﬁ  cacy and safety of 
fenoﬁ  brate 200 mg/day in 9795 type 2 diabetic patients with 
(22%) or without (78%) previous CVD. Mean baseline lipids 
were LDL-C of 119 mg/dL, TG of 153 mg/dL, and HDL-C of 
43 mg/dL. Unfortunately, only 21% of patients had a marked 
dyslipidemia deﬁ  ned (for comparison with other ﬁ  brates tri-
als) by TG  200 mg/dL and low HDL-C 40 mg/dL in men 
and 50 mg/dL in women (Scott et al 2007). At 4 months and 
study close, fenoﬁ  brate decreased respectively TG by 29% 
and 22%, LDL-C by 12% and 6% and increased HDL-C by 
5% and 1%. Fenoﬁ  brate treatment did not have a signiﬁ  cant 
effect on the primary end point (CHD death or non-fatal 
MI) reduced by only 11% (p = 0.16). There was, however, 
a signiﬁ  cant reduction (−11%, p = 0.035) in the secondary 
end point of total CVD events (a composite of CVD death, 
MI, stroke, and coronary or carotid revascularization), largely 
driven by signiﬁ  cant reductions in non-fatal MI (−24%, 
p = 0.01) and coronary revascularization (−21%, p = 0.003). 
There was a non-signiﬁ  cant increase in CHD death in the 
fenoﬁ  brate group. The FIELD investigators also reported 
a signiﬁ  cant 20% reduction of all MI events (p = 0.006) 
and a signiﬁ  cant 38% reduction in the risk of non-traumatic 
amputations (p = 0.011) with fenoﬁ  brate (Burgess et al 2007). 
Fenoﬁ  brate treatment was also associated with signiﬁ  cant 
reductions in the need for retinal laser therapy and decreased 
progression/increased regression of albuminuria (The FIELD 
study investigators 2005). The global results of FIELD have 
been considered as disappointing event if the overall CVD 
event results were positive in several regards.
Some explanations can be proposed to explain the FIELD 
results: the higher rate of statin use in the placebo group (36% 
among placebo patients by close of study versus 19% in the 
fenoﬁ  brate arm) may play a role. Among fenoﬁ  brate patients 
not receiving off-trial lipid treatment, the CVD composite end 
point was signiﬁ  cantly reduced by 19%. The poor effect of feno-
ﬁ  brate in reducing CVD events, more particularly in secondary 
prevention, could also be explained by the signiﬁ  cant increase Vascular Health and Risk Management 2008:4(5) 995
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of homocysteine levels. It has been shown that gemﬁ  brozil 
increased plasma homocysteine less than fenoﬁ  brate (Dierkes 
et al 2003; Syvanne et al 2004) and this difference could 
explain the better clinical beneﬁ  t of gemﬁ  brozil in the VA-HIT 
(Robins et al 2001; Rubins et al 2002) and HHS (Frick et al 
1987). Another hypothesis to explain the FIELD results is the 
modest effects of fenoﬁ  brate on lipid parameters; particularly 
the declining effect on HDL-C overtime could also be due to 
the fact to elevated homocysteine has been reported to reduce 
the ApoA-I expression (Mikael et al 2006).
More convincing, the relative lack of favorable effects in 
FIELD may be related to the selected population. Fibrates 
reduce CVD effectively in patients with insulin resistance/
overweight people with high TG and low HDL-C (Barter 
and Rye 2008). In FIELD, the baseline TG was lower and 
the HDL-C was higher than in HHS or VA-HIT, with a 
lower TG/HDL-C ratio (4.05) than in VA-HIT (higher ratio 
of 5.37). New complementary analyses recently reported 
(Scott et al 2007) have provided important data on the clinical 
utility of fenoﬁ  brate in mixed dyslipidemia: in the subgroup 
of 2,014 patients with low HDL-C and TG  200 mg/dL, 
fenoﬁ  brate treatment induced a signiﬁ  cant reduction of CVD 
events (13.5% in the fenoﬁ  brate group versus 17.8% in the 
placebo group, HR 0.74, p = 0.007). This highly signiﬁ  cant 
effect corresponds to a 4.3% absolute risk reduction, with a 
number need to treat of 23 to avoid 1 or more CVD events. 
The beneﬁ  cial effect of fenoﬁ  brate on macrovascular events 
appears larger among type 2 diabetic subjects with mixed 
dyslipidemia (Scott et al 2007).
Fenoﬁ  brate was generally well tolerated. A meta-analysis 
of 53 trials using ﬁ  brates has not shown any increase in non 
coronary death or cancer (Birjmohun et al 2005). The most 
frequent adverse effects were gastrointestinal symptoms, 
skin reactions and musculoskeletal symptoms (Birjmohun 
et al 2005). Some cases of liver function test and creatine 
phosphokinase abnormalities have been reported (Keating 
and Ormrod 2002; Keating and Croom 2007). In the FIELD 
trial, it has been also observed a slight but signiﬁ  cant increase 
in pancreatitis (0.8% in fenoﬁ  brate group versus 0.5% in 
placebo group) and pulmonary embolism (1.1% versus 
0.7%), and a non signiﬁ  cant increase in deep vein thrombosis 
(1.4% versus 1.0%). The excess of pancreatitis may be due 
to the increased lithogenicity of bile. The increased risk of 
venous thrombotic events may be related to the increased 
homocysteine level, a risk factor for thrombosis (Undas et al 
2005). Overall, in FIELD, rhabdomyolysis only occurred in 
three fenoﬁ  brate recipients and one placebo recipient, and 
all cases were fully resolved.
Fenoﬁ  brate is contraindicated in patients with hepatic or 
several renal dysfunction, pre-existing gallbladder disease, 
primary biliary cirrhosis or unexplained persistent liver func-
tion abnormalities. Fenoﬁ  brate potentiates the anticoagulant 
activity of coumarin and there is a warning on the concomi-
tant use of fenoﬁ  brate and cyclosporine.
Clinical efﬁ  cacy in combination
with statins
Guidelines suggest both ﬁ  brates and niacin as additions to 
statin therapy in high risk patients with persistently low levels 
of HDL-C and elevated triglycerides (Grundy et al 2004a; 
Buse et al 2007; The Task Force on Diabetes 2007). Updated 
guidelines from the NCEP ATP III recognize the potential 
of the statin-ﬁ  brate and statin-niacin combination therapies 
in patients with mixed dyslipidemia and CHD or CHD risk 
equivalents (Stone et al 2005).
Given the complementary pharmacologic proﬁ  les of 
ﬁ  brates and statins, greater clinical beneﬁ  t may be expected 
with combination therapy. However the use of ﬁ  brate/statin 
combination therapy has been rapidly restricted due to safety 
concerns, mainly an increased risk of myopathy and rhab-
domyolysis (Shek and Ferrill 2001; Farnier 2003). Several 
reviews have examined the beneﬁ  cial effects and the safety of 
a statin-ﬁ  brate combination therapy (Shek and Ferrill 2001; 
Farnier 2003; Wierzbicki et al 2003; Stefanutti et al 2004; 
Corsini et al 2005). In summary, the available evidence on 
safety clearly indicates differences in the risk of myopathy 
and rhabdomyolysis between ﬁ  brates (Alsheikh-Ali et al 
2004; Jones and Davidson 2005). In combination with a 
statin, rhabdomyolysis has been reported to be 15-fold (Jones 
and Davidson 2005) and 33-fold (Alsheikh-Ali et al 2004) 
higher with gemﬁ  brozil than with fenoﬁ  brate. Moreover the 
risk was particularly elevated when cerivastatin was use in 
combination with gemﬁ  brozil (Chang et al 2004; Graham 
et al 2004; Jones and Davidson 2005). The pharmacokinetic 
interactions between statins and ﬁ  brates have been carefully 
studied (Prueksaritanont et al 2002a; Corsini et al 2005). 
The mechanism for the higher rate of adverse interaction of 
gemﬁ  brozil versus fenoﬁ  brate with statins appears mainly 
to be interference with statin glucuronidation by gemﬁ  -
brozil. In vitro studies have demonstrated that gemﬁ  brozil 
interacts with the same family of glucuronidation enzymes 
that are involved in statin metabolism (Prueksaritanont 
et al 2002a, b). In contrast, fenoﬁ  brate was metabolized by 
different glucuronidation enzymes than those involved in 
statin metabolism (Prueksaritanont et al 2002b). Therefore, 
gemﬁ  brozil causes a 2- to 6-fold increase in the statin AUC Vascular Health and Risk Management 2008:4(5) 996
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(Corsini et al 2005). But fenoﬁ  brate has not signiﬁ  cant 
effect on the pharmacokinetics of various statins (Pan et al 
2000; Martin et al 2003; Bergman et al 2004, Gustavson 
et al 2005). Finally, clinical trial data have not reported an 
increased risk of myopathy with various statins combined 
to fenoﬁ  brate (Ellen and McPherson 1998; Farnier and 
Dejager 2000; Athyros et al 2002; Martin et al 2003; Vega 
et al 2003; Durrington et al 2004; Grundy et al 2005). In 
FIELD, among the 944 patients taking fenoﬁ  brate and statin 
combination therapy in about 2000 patient-years of use, no 
cases of rhabdomyolysis were reported (The FIELD study 
investigators 2005; Keech 2006).
All these data suggest that fenoﬁ  brate may be the pre-
ferred ﬁ  brate for use in combination with statin and guidelines 
recommend fenoﬁ  brate as the ﬁ  brate of choice for high-risk 
statin-treated patients with mixed dyslipidemia (Grundy et al 
2004b). Fenoﬁ  brate may be added to a statin when mixed 
dyslipidemia responds inadequately with monotherapy, 
although use of lower statin doses has been recommended 
in this case (Davidson et al 2007).
The results of clinical studies support the efﬁ  cacy of 
fenoﬁ  brate-statin therapy in patients with mixed dyslip-
idemia (Ellen and McPherson 1998; Athyros et al 2002; 
Vega et al 2003; Durrington et al 2004; Grundy et al 2005). 
For example, in the SAFARI trial (Grundy et al 2005), 619 
patients with mixed dyslipidemia (TG from 150 to 500 
mg/dL and LDL-C higher than 130 mg/dL) were treated 
with either simvastatin 20 mg/d or the combination of sim-
vastatin 20 mg/d plus fenoﬁ  brate 160 mg/d for 12 weeks. 
The combined treatment was associated with signiﬁ  cantly 
greater changes compared with simvastatin alone in TG 
(−43.0% versus −20.1%), LDL-C (−31.2% versus −25.8%), 
non-HDL-C (−35.3% versus −26.1%), and HDL-C (+18.6% 
versus +9.7%). In addition, combination therapy induced a 
signiﬁ  cant shift from small, dense LDL particles to larger, 
more buoyant LDL particles (Grundy et al 2005).
The same beneﬁ  cial effect on LDL subfractions has been 
observed in the DIACOR study in the group of patients with 
type 2 diabetes and mixed dyslipidemia receiving the com-
bination of simvastatin 20 mg/d and fenoﬁ  brate 160 mg/d 
(May et al 2008). The DIACOR trial has also shown that 
combination therapy has greater anti-inﬂ  ammatory effects than 
either form of monotherapy (Muhlestein et al 2006), probably 
in relation with the cross-talk between statins and PPARα 
agonists regarding pleiotropic effects (Paumelle and Staels 
2008). Several trials are ongoing to evaluate more precisely 
the complementary beneﬁ  cial effects of fenoﬁ  brate for patients 
with mixed dyslipidemia not at goals on statin therapy.
All these data may support the use of fenoﬁ  brate-statin 
combination therapy to achieve a global lipid and vascular 
control and suggest that atherosclerosis and CVD beneﬁ  ts 
may be greater with combination therapy, but direct evi-
dence of these beneﬁ  ts is not yet available. Hopefully, the 
ongoing Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) study was designed to evaluate whether adding 
fenoﬁ  brate to simvastatin can reduce CVD risk beyond the risk 
reduction with simvastatin alone in type 2 diabetic patients 
(The ACCORD Study Group 2007; Ginsberg et al 2007).
Clinical efﬁ  cacy in combination therapy 
with other agents
Although statins are the drug of ﬁ  rst choice in patients with 
mixed dyslipidemia, the use of statins may be limited by 
intolerance or poor response in monotherapy.
In patients who are unable to tolerate statin therapy, two 
alternative combination therapies with fenoﬁ  brate can be 
proposed at patients with mixed dyslipidemia, either feno-
ﬁ  brate-ezetimibe or fenoﬁ  brate-colesevelam. The efﬁ  cacy 
and safety of fenoﬁ  brate plus ezetimibe combination therapy 
has been evaluated in 625 patients with mixed dyslipidemia 
[TG from 200 to 500 mg/dL, LDL-C from 130 to 220 mg/dL 
(100–180 mg/dL in patients with diabetes)] (Farnier et al 
2005; McKenney et al 2006) randomized to received one of 
the four daily treatments: placebo, ezetimibe 10 mg, feno-
ﬁ  brate 160 mg and fenoﬁ  brate 160 mg + ezetimibe 10 mg 
during 12 weeks. The complementary effects of fenoﬁ  brate 
and ezetimibe improve the overall atherogenic lipid proﬁ  le, 
with decreases in LDL-C of 20.4%, non-HDL-C of 30.4%, 
TG of 44.0%, and increase in HDL-C of 19.0% (Farnier et al 
2005). Moreover, the co-administration of fenoﬁ  brate and 
ezetimibe produced complementary and favorable changes in 
lipoprotein subfractions, promoting a shift in the LDL particle 
distribution proﬁ  le toward larger, more buoyant particles 
(Farnier et al 2005; Tribble et al 2008). After completing the 
12-week, randomized, double-blind base study, 576 patients 
entered in a 48-week, double-blind extension study, during 
which they received fenoﬁ  brate or fenoﬁ  brate plus ezeti-
mibe (McKenney et al 2006). Improvements from baseline 
in LDL-C (−22.0% versus −8.6%), non-HDL-C (−31.6% 
versus −19.4%), TG (−46.0% versus −41.8%) and HDL-C 
(20.9% versus 17.8%) levels were signiﬁ  cantly greater with 
fenofibrate-ezetimibe combination therapy than with 
fenoﬁ  brate alone. The combination of ezetimibe plus feno-
ﬁ  brate was well tolerated during both the base study (Farnier 
et al 2005) and the extension study (McKenney et al 2006). 
In the base study, one patient receiving combination therapy Vascular Health and Risk Management 2008:4(5) 997
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was discontinued after being diagnosed with cholelithiasis 
and subsequent cholecystectomy. In the extension study, the 
proportion of patients with cholecystectomy was not signiﬁ  -
cantly different between treatments, but this study was not 
designed to assess this infrequent biliary adverse event. It 
has been reported that fenoﬁ  brate may increase cholesterol 
excretion into bile and ezetimibe has inconsistent effects on 
biliary cholesterol in animal models (Farnier 2007).
Another alternative to statin therapy is a bile acid 
sequestrant (BAS) combined with a ﬁ  brate. Colesevelam 
has become the preferred BAS because it is well-tolerated 
compared to older BAS and lowers LDL-C levels an average 
of 15% to 18%. The complementary efﬁ  cacy of colesevelam 
added to fenoﬁ  brate has been evaluated in 129 patients 
with mixed dyslipidemia treated 8 weeks by fenoﬁ  brate 
160 mg/d, then randomized to receive either colesevelam 
3.75 g/d or placebo (McKenney et al 2005). Compared with 
fenoﬁ  brate monotherapy, the combination of fenoﬁ  brate 
and colesevelam signiﬁ  cantly reduced LDL-C (−17.0%) 
and non-HDL-C (−21.0%) from baseline, without affecting 
the TG-lowering or HDL-C raising effects of fenoﬁ  brate 
(McKenney et al 2005).
Finally in patients with severe mixed dyslipidemia or 
poor responders to statin monotherapy, a new option is a 
triple therapy using statin, ezetimibe and fenoﬁ  brate. The 
efﬁ  cacy of the co-administration of ezetimibe/simvastatin 
10/20 mg + fenofibrate 160 mg has been evaluated 
in 611 patients with mixed dyslipidemia (TG from 
150 to 500 mg/dL, LDL-C from 130 to 220 mg/dL 
[100–180 mg/dL in patients with diabetes]) randomized to 
receive one of the four treatments ezetimibe/simvastatin 
10/20 mg + fenoﬁ  brate 160 mg, ezetimibe 10/20 mg, 
fenoﬁ  brate 160 mg, or placebo for 12 weeks (Farnier 
et al 2007). The triple therapy improved the overall 
atherogenic lipid proﬁ  le (−46% for LDL-C, −50% for TG 
and non-HDL-C, −45% for ApoB, +19% for HDL-C) with 
a signiﬁ  cant shift of small, dense LDL to larger particles 
(Farnier et al 2007). Although the co-administration of 
fenoﬁ  brate and ezetimibe/simvastatin was well tolerated 
in this short-term study, the long-term safety and clinical 
outcome beneﬁ  ts remain to be determined.
Rational prescribing of fenoﬁ  brate 
in mixed dyslipidemias
Although statins are indicated as ﬁ  rst-line therapy for 
patients with mixed dyslipidemia, statin treatment may 
be limited by the failure to reach LDL-C and non-HDL-C 
targets and by intolerance or poor-response in monotherapy. 
Moreover, many patients remain at risk of CVD despite 
having LDL-C levels below recommended targets. Thus, 
increasing attention is being focused on other lipoprotein 
fractions such as HDL and triglycerides, as potential targets 
of therapy. There is recent evidence that abnormalities of 
the triglyceride-HDL axis are especially associated with 
adverse cardiovascular outcomes. In FIELD, fenoﬁ  brate 
reduced CVD effectively in patients with insulin resis-
tance, low HDL-C, and high TG. However, prescribing 
recommendations are constrained by a lack of clinical trial 
evidence of fenoﬁ  brate-statin therapy. Nevertheless, it is 
possible to propose a rational prescribing of fenoﬁ  brate in 
mixed dyslipidemia:
1.  For high-risk patients not at their non-HDL-C goals 
and with high TG and/or low HDL-C levels, a statin-
fenoﬁ  brate combination therapy can be required to 
control all lipid abnormalities. In light of the increasing 
prevalence of diabetes and the metabolic syndrome, the 
clinical use of fenoﬁ  brate combined with a statin may 
be likely to increase. Data from prospective outcome 
studies are required to evaluate the beneﬁ  ts of this 
approach.
In severe mixed dyslipidemia, when the LDL-C and 
non-HDL-C goals are not reached with a usual dose 
of statin and fenoﬁ  brate, a triple therapy with a statin, 
fenoﬁ  brate, and ezetimibe can be used to avoid the 
highest statin doses and with the same caution as statin-
fenoﬁ  brate therapy.
2.  For patients with intolerance to statin therapy or if a 
statin is inappropriate or contraindicated, fenoﬁ  brate 
monotherapy is indicated in mixed dyslipidemia. 
However, particularly for high risk patients, the LDL-
C and/or non-HDL-C goals are often not attained 
with fenoﬁ  brate alone. A combination of fenoﬁ  brate 
wth ezetimibe or colesevelam can be useful for these 
patients.
In conclusion, despite the impressive beneﬁ  ts achieved 
by LDL-C lowering using statins, there are compelling 
reasons to consider other lipoprotein abnormalities pres-
ent in mixed dyslipidemia as risk factors. Fenoﬁ  brate has 
a favorable effect on the global atherogenic lipoprotein 
proﬁ  le and may offer important treatment alternatives as 
second-line therapy.
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